January 23, 2017
Biotech firms backs controversial CRISPR challenger
news@nature.com - Fetched: January 23rd, 2017, 7:00am UTC
What Novozymes might do with the NgAgo protein, claimed by some to be a powerful gene-editor, is still unclear.
Nature News doi: 10.1038/nature.2017.21343